Document is current
Any future updates will be listed below
-
Authors
Enzendorfer, Marie Louise https://orcid.org/0009-0003-6122-2395
Reiter, Gregor S. https://orcid.org/0000-0001-7661-4015
Bogunović, Hrvoje https://orcid.org/0000-0002-9168-0894
Riedl, Sophie https://orcid.org/0000-0003-0003-0886
Mai, Julia https://orcid.org/0000-0002-0528-9742
Schrittwieser, Johannes
Stapf, Christoph
Mares, Virginia
Mihelčič, Matjaž
Little, Julie-Anne https://orcid.org/0000-0001-5242-8066
Jaki-Mekjavić, Polona
Barthelmes, Daniel
Hatz, Katja
Zarranz-Ventura, Javier https://orcid.org/0000-0003-2338-8143
Creuzot-Garcher, Catherine
Hogg, Ruth https://orcid.org/0000-0001-9413-2669
Sadeghipour, Amir
Schmidt-Erfurth, Ursula https://orcid.org/0000-0002-7788-7311
,
Turk, Matjaž
Birner, Klaudia
Eidenberger, Anna
Sacu, Stefan
Pinetz, Thomas
Hucke, Veit
Lachinov, Dmitrii
Emre, Taha
Little, Julie-Ann
Eckert, Fabienne
Gumpelmayer, Peter
Jaki-Mekjavić, Polona
Benda, Polona Zaletel
Drnovšek, Fran
Hadalin, Vlasta
Klemenc, Barbara
Perovšek, Darko
Rudolph, Katrin
Timoceanu, Luca
Hatz, Katja
Buck, Judith
Monnet, Charlotte
Plasencia, Christina
Heck, Katharina
Zarranz-Ventura, Javier
Mendez-Mourelle, Andrea
Castro-Domínguez, Rafael
Vila, Irene
Pereira, Alicia
Bernal-Morales, Carolina
Giralt, Lena
Grau, Josep
Bilbao, Valentina
Marías-Perez, Sonia
Marjalizo, Pau
Gabrielle, Pierre Henry
Steinberg, Laure-Anne
Peto, Tunde
Dalton, Lucia
Beirne, Raymond
McConnell, Emma
Brannigan-Hogarth, Deirdre
McKeown, Jill
Rundle, Lucy
Telford, Jill
Vandevyver, Stephen
Donaldson, Faith
Long, Judith
Black, Graeme
Hrbacek, Vedran
Whitby, Ariadne
Okcuoglu, Doruk
Ambichler, Patricia
Lenhart, Miriam
Šale, Sanja
Radić, Gabrijela
Rogina, Lucija
Rašković, Slaven
Lednicki, Nikolina
- License Information
-
More Information
Article History
Received: 19 September 2025
Revised: 1 April 2026
Accepted: 14 April 2026
First Online: 5 May 2026
Competing interests
: MLE: None; GSR: ADARx (C), Apellis (C), Bayer (C), Boehringer Ingelheim (C), Espansione (C), Nordic Pharma (C), Roche (C), VeonGen (C), RetInSight (F); HB: Heidelberg Engineering (F); SR: None; JM: None; JS: None; CS: None; VM: RetInSight (C); MM: None; JL: None; PJM: Abbvie (H), Bayer (C), Roche (H); DB: Alcon (C), Bayer (C); KH: Allergan/AbbVie (C), Bayer (C), Roche (C), Sandoz (C), Astellas (C), Amgen (C); JZV: Allergan/AbbVie (C, F), Adverum (C), Alcon (C), Alimera (C), Bausch & Lomb (C), Bayer (C, F), Brill Pharma (C), DORC (C), Esteve (C), Novartis (C, F), Roche (C, F), Sandoz (C), Topcon Healthcare (C), Ulma Medical Tech (C), and Zeiss (C). Member of the Eye editorial board; CCG: AbbVie (C), Alcon (C), Bayer (C, F), DORC (C), Horus (C, F), Novartis (C), Roche (C), Théa (C, F); RH: Heidelberg Engineering (F), Okko Health (F); AS: RetInSight (E); USE: AbbVie (C), Alcon (C), Apellis (C, F), Astellas (C), Aviceda (C), Bayer (C), Complement Therapeutics (C), Genentech (F), Heidelberg Engineering (F), Kodiak (C, F), Medscape (C), Roche (C, F), Topcon (C)
